74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Exact Sciences Corp
Open
SectorHealthcare
43.76 3.55
Overview
Share price change
24h
Min
42.62
Max
44.3
Income | -826M -865M |
|---|---|
Sales | 4.8M 713M |
EPS | -0.24 |
Profit margin | -121.188 |
Employees | 6,900 |
EBITDA | -841M -815M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +60.56% upside |
Next Earnings | 1 May 2025 |
|---|
Market Cap | -2.3B 8.1B |
|---|---|
Previous open | 40.21 |
Previous close | 43.76 |
News Sentiment
By Acuity
50%
50%
169 / 385 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
Exact Sciences Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Exact Sciences Corp Forecast
Price Target
By TipRanks
60.56% upside
12 Months Forecast
Average 66.76 USD 60.56%
High 80 USD
Low 52 USD
Based on 18 Wall Street analysts offering 12 month price targets forExact Sciences Corp - Dist in the last 3 months.
Sentiment
By Acuity
169 / 385 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Exact Sciences Corp
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
